The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending Blincyto (blinatumomab) from...
Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include overall survival...
Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for Blincyto (blinatumomab) to include...
The European Commission has granted conditional marketing authorization for Blincyto (blinatumomab), from Amgen, for the treatment of adults with Philadelphia...
Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus (brexucabtagene autoleucel)(KTE 19) in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Amgen has announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival...
Amgen announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data...
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction...
Amgen announced new data from a prespecified interim analysis of the Phase III TOWER study, in which Blincyto (blinatumomab) demonstrated...
BeiGene announced that the China National Medical Products Administration (NMPA) has granted conditional approval of Blincyto (blinatumomab) for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).